• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nordisk wins label update for weight loss drug-device combo

April 27, 2017 By Sarah Faulkner

Novo NordiskNovo Nordisk (NYSE:NVO) said today that the FDA approved an updated label for its Saxenda liraglutide weight loss medicine. The therapy’s new label will include data showing that half of patients who received Saxenda and lost at least 5% of their weight after 56 weeks maintained their weight loss for 3 years.

The update is based on data from the company’s Scale obesity and pre-diabetes 3-year trial, which evaluated the long-term safety and efficacy of Saxenda in 3,731 adults.

All of the study’s participants were treated for 56 weeks and 2,254 patients with pre-diabetes were treated for 160 weeks. Patients were divided in a 2:1 ratio into the Saxenda arm or the placebo branch.

After 160 weeks, 50% of patients in the Saxenda arm lost at least 5% of their body weight, compared to 43% of patients in the placebo arm.

The data from this long-term study are consistent with Saxenda’s established safety profile, according to Nordisk. The medicine’s most common side effects were gastrointestinal.

“We are pleased by the FDA’s approval, which marks Saxenda as the only weight-loss and management medicine in a pen supported by long-term safety and efficacy data. The addition of this clinical data to the Saxenda label underscores Novo Nordisk’s dedication to building a robust body of scientific evidence, highlighting the chronic, progressive nature of the disease of obesity,” VP & chief medical officer Dr. Todd Hobbs said in prepared remarks. “We continue in our long-term commitment to improve the lives of people with obesity by partnering with the community on education and advocacy, increasing access to care, and advancing medical management of the disease.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS